TRANSGENE (EPA:TNG) | Finanzwire

Basculer en Français

9774	Companies
195575	Keywords
126559	Articles
103968	Press releases

Home
Companies
TRANSGENE

BRIEF

published on 11/25/2025 at 20:46, 2 months 4 days ago

Temporary Suspension of Trading in Transgene Shares on Euronext Paris

Euronext Paris Biotechnology Capital Increase Transgene Trading Suspended
PRESS RELEASE

published on 11/25/2025 at 20:41, 2 months 4 days ago

Transgene Announces the Temporary Suspension of Trading of its Shares on Euronext Paris
Transgene requests temporary suspension of trading on Euronext Paris pending capital increase results

Euronext Paris Trading Capital Increase Suspension Transgene
BRIEF

published on 11/25/2025 at 19:20, 2 months 4 days ago

Transgene Launches €105 Million Fundraising Initiative

Biotechnology Investment Transgene Fundraising Myvac® Program Cancer Vaccine Development Institutional And Retail Offerings
PRESS RELEASE

published on 11/25/2025 at 19:15, 2 months 4 days ago

Transgene launches a fundraising campaign for approximately 105 million euros
Transgene launches a fundraising of approximately 105 million euros through new share issuance to investors. Funding to advance myvac program for personalized cancer vaccines and ensure financial stability until early 2028

Fundraising Financial Stability Cancer Vaccines Transgene Myvac Program
BRIEF

published on 11/06/2025 at 08:35, 2 months 23 days ago

Transgene to Present VacDesignR® Tool at ESMO AI 2025

Transgene VacDesignR® INTV ESMO AI 2025 HPV-negative Cancer
PRESS RELEASE

published on 11/06/2025 at 08:30, 2 months 23 days ago

Transgene to Showcase Potential of Proprietary VacDesignR® Computational Tool to Optimize Individualized Therapeutic Cancer Vaccines
Transgene to present VacDesignR® tool at ESMO-AI 2025 for optimized cancer vaccine design. Tool enhances virus efficiency and yield for individualized therapies

Cancer Vaccines Computational Tool Transgene VacDesignR ESMO-AI 2025
BRIEF

published on 11/04/2025 at 17:55, 2 months 25 days ago

Transgene presents its progress and financial situation as of Q3 2025

Funding Immunotherapy Transgene TG4050 SITC 2025
PRESS RELEASE

published on 11/04/2025 at 17:50, 2 months 25 days ago

Transgene Provides Business and Financial Update for Q3 2025
Transgene provides business and financial update for Q3 2025, including immunogenicity data of INTV TG4050 in Phase I study on HNSCC. Company focuses on cancer immunotherapies

Financial Update Transgene INTV TG4050 Cancer Immunotherapies HNSCC
BRIEF

published on 10/20/2025 at 08:35, 3 months 9 days ago

Transgene and BioInvent's BT-001 Shows Promising Antitumor Activity

Cancer Immunotherapy Transgene Oncolytic Virus BT-001 Antitumoral Activity
PRESS RELEASE

published on 10/20/2025 at 08:30, 3 months 9 days ago

Transgene and BioInvent’s Armed Oncolytic Virus BT-001 Shows Positive Local, Abscopal, and Sustained Antitumoral Activity in Advanced Refractory Tumors
Transgene and BioInvent's BT-001 oncolytic virus in combination with pembrolizumab shows positive antitumoral activity in refractory tumors. Exciting clinical data presented at ESMO 2025

Transgene Oncolytic Virus BioInvent BT-001 Pembrolizumab

Accesswire

Published on 01/30/2026 at 02:15, 5 hours 17 minutes ago

Canex Metals Announces Success of Gold Basin Take-Over Bid, Extension of the Partial Revocation of the Cease-Trade Order Imposed on Gold Basin, Waiver of All Remaining Conditions, Initiation of the Share Take Up Process, and Mandatory 10-Day Extension
Published on 01/30/2026 at 00:00, 7 hours 32 minutes ago

LIR Life Sciences Reports Positive Interim Preclinical Results from Comparative Animal Study of Novel CPP-Enabled Transdermal Delivery of GLP/GIP-Based Therapies
Published on 01/29/2026 at 23:00, 8 hours 32 minutes ago

PPX Mining Announces Filing of 2025 Audited Financial Statements and MD&A
Published on 01/29/2026 at 18:45, 12 hours 47 minutes ago

Silver Spruce Appoints Vice-President of Exploration
Published on 01/29/2026 at 18:00, 13 hours 32 minutes ago

PPX Mining Announces Grant of Restricted Share Units and Deferred Share Units

View all ACCESSWIRE

EQS Group

Published on 01/30/2026 at 07:00, 32 minutes ago

Unbroken record series with high revenue momentum for cloud and subscriptions – 20th record year in a row for revenue and earnings
Published on 01/30/2026 at 04:30, 3 hours 1 minute ago

A First Look at AI in the Real World: AWE 2026 Opens This March in Shanghai
Published on 01/30/2026 at 03:35, 3 hours 56 minutes ago

Bybit Unveils 2026 Vision as "The New Financial Platform," Expanding Beyond Exchange Into Global Financial Infrastructure
Published on 01/30/2026 at 00:07, 7 hours 24 minutes ago

EQS-Adhoc: Dexus Finance Pty Limited: Appointment of independent non-executive director
Published on 01/29/2026 at 21:02, 10 hours 29 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Avadel Pharmaceuticals plc

Les Echos

Published on 01/29/2026 at 18:00, 13 hours 32 minutes ago

GUILLEMOT CORPORATION: FULL-YEAR 2025 CONSOLIDATED TURNOVER UP 2%
Published on 01/29/2026 at 17:45, 13 hours 47 minutes ago

LANSON-BCC ANNOUNCES 2025 REVENUES AND FINALISES THE ACQUISITION OF HEIDSIECK & C° MONOPOLE
Published on 01/29/2026 at 17:45, 13 hours 47 minutes ago

Cegedim generated LFL revenue growth of 1.1% in 2025
Published on 01/29/2026 at 17:40, 13 hours 52 minutes ago

ALTEN: Annual revenue 2025
Published on 01/29/2026 at 10:07, 21 hours 24 minutes ago

Deezer confirms demonetization of up to 85% of AI-music streams due to fraud and moves to sell AI-detection tech

View all LES ECHOS COMFI WIRE